PUMA BIOTECHNOLOGY, INC. (PBYI) Cash Flow Statement
PUMA BIOTECHNOLOGY, INC. (PBYI) generated $41.1M of operating cash flow over the twelve months to 2026-06-30, spent -$10000 on capital expenditure and had free cash flow of $41.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PBYIPUMA BIOTECHNOLOGY, INC.Follow PBYI — free
—
Price chart with a free account
- Market cap
- 568.9M
- P/E TTM
- 21.2
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -172.5 | -24.1 | 22.4 | 0.8 | 20.7 | -15.8 | 27.0 | 38.9 | 41.8 | 41.1 | |
| Capital expenditure | 0.4 | 0.4 | 0.3 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | |
| Free cash flow | -172.9 | -24.5 | 22.1 | 0.7 | 20.7 | -15.8 | 26.9 | 38.9 | 41.7 | 41.2 | |
| Stock-based compensation | 108.7 | 86.9 | 57.3 | 36.6 | 32.6 | 11.8 | 10.2 | 8.2 | 6.9 | — |
USD millions · SEC XBRL
PUMA BIOTECHNOLOGY, INC. — questions
- What is PUMA BIOTECHNOLOGY, INC.'s operating cash flow?
- $41.1M over the twelve months to 2026-06-30.
- How much does PUMA BIOTECHNOLOGY, INC. spend on capital expenditure?
- -$10000 over the twelve months to 2026-06-30.
- What is PUMA BIOTECHNOLOGY, INC.'s free cash flow?
- $41.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from PUMA BIOTECHNOLOGY, INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.